# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Needham analyst Mike Matson reiterates Steris (NYSE:STE) with a Hold.
JMP Securities analyst David Turkaly reiterates Steris (NYSE:STE) with a Market Outperform and maintains $265 price target.
Stephens & Co. analyst Jacob Johnson reiterates Steris (NYSE:STE) with a Overweight and maintains $260 price target.
Fiscal 2025 Outlook Reiterated
Steris (NYSE:STE) reported quarterly earnings of $2.03 per share which beat the analyst consensus estimate of $1.98 by 2.53 per...
JMP Securities analyst David Turkaly reiterates Steris (NYSE:STE) with a Market Outperform and maintains $265 price target.
Toast, Teva, Vistra, Equinix, Applovin, IFF, Constellation, Emerson, IP, and STERIS were top performers last week. Are they in ...
Piper Sandler analyst Jason Bednar reiterates Steris (NYSE:STE) with a Neutral and raises the price target from $220 to $225.